🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07158437
Active, not recruiting Phase 1

Phase 1 Study of SL-325 in Healthy Volunteers

NCT07158437 · tracked via the Priya Life Science USA tracker
Sponsor
Shattuck Labs, Inc.
Phase
Phase 1
Started
2025-09-18
Last updated
2026-04-30

Condition(s) studied

Healthy Volunteers

Investigational drug(s) / intervention(s)

SL-325Placebo (Normal Saline)

SL-325: DR3 blocking antibody

Placebo (Normal Saline): Normal saline

Study summary

This first-in-human study is a randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose study of SL-325 in healthy volunteers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Provide signed informed consent 2. 18-55 years of age, inclusive, at the time of signing the informed consent form 3. Body mass index of 18-32 kg/m2, inclusive, and a total body weight \> 50 kg 4. Laboratory values within normal limits or any abnormalities deemed not clinically significant by the Investigator 5. Participant agrees to practice birth control measures Exclusion Criteria: 1. History or presence of a clinically significant infectious disease or hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, neurologic, or psychiatric abnormality 2. Any clinically significant abnormality on vital signs, electrocardiogram (ECG), or laboratory parameters 3. History of regular alcohol consumption within 6 months of Screening 4. Positive test for use of drugs or alcohol at Screening 5. History of use of tobacco- or nicotine-containing products within 3 months of Screening 6. History of infusion-related reaction or allergic reaction upon receipt of an IV infusion 7. Positive hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (HIV) test at Screening 8. Blood donation within 90 days prior to Day -1 or plasma donation within 1 week prior to Day 1 9. Receipt of specific medications within a specified time period 10. Women who are currently breastfeeding or have a positive pregnancy test

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Celerion Lincoln Nebraska

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07158437 on ClinicalTrials.gov ↗ ← All trials in the USA